Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basisQ1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP ...
A strategic investor. Vivos, a Nasdaq‑listed leader in the treatment of obstructive sleep apnea, becomes an 11% shareholder in SOD Sciences, and SOD becomes a holder of Vivos convertible preferred ...
I’m an 85-year-old woman. I took the Cologuard test a month ago, and it came back positive. My gastrointestinal doctor said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results